Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Inhibition of Rho kinases increases directional motility of microvascular endothelial cells.

Breyer J, Samarin J, Rehm M, Lautscham L, Fabry B, Goppelt-Struebe M.

Biochem Pharmacol. 2012 Mar 1;83(5):616-26. doi: 10.1016/j.bcp.2011.12.012. Epub 2011 Dec 16.

PMID:
22192821
2.

Cdc42 and RhoA have opposing roles in regulating membrane type 1-matrix metalloproteinase localization and matrix metalloproteinase-2 activation.

Ispanovic E, Serio D, Haas TL.

Am J Physiol Cell Physiol. 2008 Sep;295(3):C600-10. doi: 10.1152/ajpcell.00460.2007. Epub 2008 Jun 18.

PMID:
18562481
3.

Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis.

Kroll J, Epting D, Kern K, Dietz CT, Feng Y, Hammes HP, Wieland T, Augustin HG.

Am J Physiol Heart Circ Physiol. 2009 Mar;296(3):H893-9. doi: 10.1152/ajpheart.01038.2008. Epub 2009 Jan 30.

PMID:
19181962
4.

Endothelial repair in stented arteries is accelerated by inhibition of Rho-associated protein kinase.

Hsiao ST, Spencer T, Boldock L, Prosseda SD, Xanthis I, Tovar-Lopez FJ, Van Beusekom HM, Khamis RY, Foin N, Bowden N, Hussain A, Rothman A, Ridger V, Halliday I, Perrault C, Gunn J, Evans PC.

Cardiovasc Res. 2016 Dec;112(3):689-701. Epub 2016 Sep 26. Erratum in: Cardiovasc Res. 2017 Jan;113(1):80.

5.

Fasudil attenuates lipopolysaccharide-induced acute lung injury in mice through the Rho/Rho kinase pathway.

Li Y, Wu Y, Wang Z, Zhang XH, Wu WK.

Med Sci Monit. 2010 Apr;16(4):BR112-118.

PMID:
20357711
6.

Enhancement of endothelial progenitor cell numbers and migration by H1152, a Rho kinase specific inhibitor.

O E, Lee SW, Lee HS, Lim HS, Ahn HY, Shin JC, Kim Y, Joe YA.

Biosci Biotechnol Biochem. 2012;76(1):172-5. Epub 2012 Jan 7.

7.

Fasudil-induced hypoxia-inducible factor-1alpha degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells.

Takata K, Morishige K, Takahashi T, Hashimoto K, Tsutsumi S, Yin L, Ohta T, Kawagoe J, Takahashi K, Kurachi H.

Mol Cancer Ther. 2008 Jun;7(6):1551-61. doi: 10.1158/1535-7163.MCT-07-0428.

8.

Rho kinase inhibition by fasudil suppresses lipopolysaccharide-induced apoptosis of rat pulmonary microvascular endothelial cells via JNK and p38 MAPK pathway.

Liu H, Chen X, Han Y, Li C, Chen P, Su S, Zhang Y, Pan Z.

Biomed Pharmacother. 2014 Apr;68(3):267-75. doi: 10.1016/j.biopha.2013.12.003. Epub 2013 Dec 24.

PMID:
24406296
9.

Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage.

Arita R, Hata Y, Nakao S, Kita T, Miura M, Kawahara S, Zandi S, Almulki L, Tayyari F, Shimokawa H, Hafezi-Moghadam A, Ishibashi T.

Diabetes. 2009 Jan;58(1):215-26. doi: 10.2337/db08-0762. Epub 2008 Oct 7.

10.

Inhibition of Rho-kinase protects cerebral barrier from ischaemia-evoked injury through modulations of endothelial cell oxidative stress and tight junctions.

Gibson CL, Srivastava K, Sprigg N, Bath PM, Bayraktutan U.

J Neurochem. 2014 Jun;129(5):816-26. doi: 10.1111/jnc.12681. Epub 2014 Mar 18.

11.

The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models.

Ying H, Biroc SL, Li WW, Alicke B, Xuan JA, Pagila R, Ohashi Y, Okada T, Kamata Y, Dinter H.

Mol Cancer Ther. 2006 Sep;5(9):2158-64.

12.

Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1α in human ovarian cancer cells.

Ohta T, Takahashi T, Shibuya T, Amita M, Henmi N, Takahashi K, Kurachi H.

Cancer Biol Ther. 2012 Jan 1;13(1):25-33. doi: 10.4161/cbt.13.1.18440.

PMID:
22336585
13.

HIF-1α activation results in actin cytoskeleton reorganization and modulation of Rac-1 signaling in endothelial cells.

Weidemann A, Breyer J, Rehm M, Eckardt KU, Daniel C, Cicha I, Giehl K, Goppelt-Struebe M.

Cell Commun Signal. 2013 Oct 21;11:80. doi: 10.1186/1478-811X-11-80.

14.

Rho kinase inhibitors stimulate the migration of human cultured osteoblastic cells by regulating actomyosin activity.

Zhang X, Li C, Gao H, Nabeka H, Shimokawa T, Wakisaka H, Matsuda S, Kobayashi N.

Cell Mol Biol Lett. 2011 Jun;16(2):279-95. doi: 10.2478/s11658-011-0006-z. Epub 2011 Mar 9.

PMID:
21394446
15.

Matrix-independent stimulation of human tubular epithelial cell migration by Rho kinase inhibitors.

Kroening S, Stix J, Keller C, Streiff C, Goppelt-Struebe M.

J Cell Physiol. 2010 Jun;223(3):703-12. doi: 10.1002/jcp.22079.

PMID:
20175114
16.

The Rho-kinase inhibitor H-1152P suppresses the wound-healing activities of human Tenon's capsule fibroblasts in vitro.

Tura A, Grisanti S, Petermeier K, Henke-Fahle S.

Invest Ophthalmol Vis Sci. 2007 May;48(5):2152-61.

PMID:
17460274
17.

Corneal Endothelial Cell Migration and Proliferation Enhanced by Rho Kinase (ROCK) Inhibitors in In Vitro and In Vivo Models.

Meekins LC, Rosado-Adames N, Maddala R, Zhao JJ, Rao PV, Afshari NA.

Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6731-6738. doi: 10.1167/iovs.16-20414.

PMID:
27951595
18.

Endothelial microparticle formation by angiotensin II is mediated via Ang II receptor type I/NADPH oxidase/ Rho kinase pathways targeted to lipid rafts.

Burger D, Montezano AC, Nishigaki N, He Y, Carter A, Touyz RM.

Arterioscler Thromb Vasc Biol. 2011 Aug;31(8):1898-907. doi: 10.1161/ATVBAHA.110.222703. Epub 2011 May 19.

19.

Rho-kinase and myosin II activities are required for cell type and environment specific migration.

Nakayama M, Amano M, Katsumi A, Kaneko T, Kawabata S, Takefuji M, Kaibuchi K.

Genes Cells. 2005 Feb;10(2):107-17.

20.

Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo.

Deng L, Li G, Li R, Liu Q, He Q, Zhang J.

Cancer Biol Ther. 2010 Jun 1;9(11):875-84. Epub 2010 Jun 26.

PMID:
20364104

Supplemental Content

Support Center